Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | Chief Financial Officer | February 22, 2024 | February 23, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cullinan Therapeutics, Inc.
Report date February 22, 2024 · Filed February 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 133,919 |
Reported balance
After 2024-02-22 transaction · row 1
1 source rowRow 1 · 2024-02-22 · Grant · Acquired 50,000 · Balance 133,919 F1: The shares underlying the restricted stock unit vest on an annual basis over four years. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.54 · Expires 2034-02-22 | Direct | 100,000 |
Reported balance
After 2024-02-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-22 · Grant · Acquired 100,000 · Balance 100,000 F2: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the restricted stock unit vest on an annual basis over four years.
F2: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
XOMA Royalty Corp
Report date July 14, 2026 · Filed July 15, 2026
Section 16 reporting ended · disclosed 2026-07-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-14 transaction · row 1
1 source rowRow 1 · 2026-07-14 · Other · Disposed 103,906 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F2: At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the "Closing Amount"), plus (ii) an amount of contingent value rights (each, a "CVR") representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the "Merger Consideration"). F3: At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Expires 2029-03-11 | Direct | 0 |
Reported balance
After 2026-07-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-14 · Disposition to issuer · Disposed 126,924 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F4: Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award ("PSU") automatically converted into and was substituted with a restricted stock unit award (each, a "Converted PSU") with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the "Target Shares" (as the term "Target Shares" is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of "Target Shares" as to which, as of immediately prior to the Effective Time, the "Performance-Requirement" has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the "Target Shares" underlying such PSU as to which the "Performance-Requirement" would be satisfied if the "Closing Price" (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over F5: (Continued from footnote 4) (B) the number of "Target Shares" as to which, as of immediately prior to the Effective Time, the "Performance-Requirement" has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-05-18 | Direct | 0 |
Reported balance
After 2026-07-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-14 · Disposition to issuer · Disposed 26,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F4: Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award ("PSU") automatically converted into and was substituted with a restricted stock unit award (each, a "Converted PSU") with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the "Target Shares" (as the term "Target Shares" is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of "Target Shares" as to which, as of immediately prior to the Effective Time, the "Performance-Requirement" has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the "Target Shares" underlying such PSU as to which the "Performance-Requirement" would be satisfied if the "Closing Price" (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over F5: (Continued from footnote 4) (B) the number of "Target Shares" as to which, as of immediately prior to the Effective Time, the "Performance-Requirement" has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
F2: At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the "Closing Amount"), plus (ii) an amount of contingent value rights (each, a "CVR") representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the "Merger Consideration").
F3: At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
F4: Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award ("PSU") automatically converted into and was substituted with a restricted stock unit award (each, a "Converted PSU") with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the "Target Shares" (as the term "Target Shares" is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of "Target Shares" as to which, as of immediately prior to the Effective Time, the "Performance-Requirement" has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the "Target Shares" underlying such PSU as to which the "Performance-Requirement" would be satisfied if the "Closing Price" (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over
F5: (Continued from footnote 4) (B) the number of "Target Shares" as to which, as of immediately prior to the Effective Time, the "Performance-Requirement" has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2026 Filed Jul 15, 2026 01:45 UTC | XOMA Royalty Corp XOMA · Entity 30207 | Disposition to issuerPerformance Stock Units · Derivative | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-303720 · ownership.xml · derivative · entry 3 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2026-05-18 F1 · derivative.exercise_price: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F4 · derivative.exercise_price: Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award ("PSU") automatically converted into and was substituted with a restricted stock unit award (each, a "Converted PSU") with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the "Target Shares" (as the term "Target Shares" is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of "Target Shares" as to which, as of immediately prior to the Effective Time, the "Performance-Requirement" has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the "Target Shares" underlying such PSU as to which the "Performance-Requirement" would be satisfied if the "Closing Price" (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over F5 · derivative.exercise_price: (Continued from footnote 4) (B) the number of "Target Shares" as to which, as of immediately prior to the Effective Time, the "Performance-Requirement" has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU. F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F4 · derivative.exercise_date: Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award ("PSU") automatically converted into and was substituted with a restricted stock unit award (each, a "Converted PSU") with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the "Target Shares" (as the term "Target Shares" is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of "Target Shares" as to which, as of immediately prior to the Effective Time, the "Performance-Requirement" has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the "Target Shares" underlying such PSU as to which the "Performance-Requirement" would be satisfied if the "Closing Price" (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over F5 · derivative.exercise_date: (Continued from footnote 4) (B) the number of "Target Shares" as to which, as of immediately prior to the Effective Time, the "Performance-Requirement" has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU. Read SEC document |
| July 14, 2026 Filed Jul 15, 2026 01:45 UTC | XOMA Royalty Corp XOMA · Entity 30207 | Disposition to issuerPerformance Stock Units · Derivative | 126,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-303720 · ownership.xml · derivative · entry 2 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 126,924 shares Expires 2029-03-11 F1 · derivative.exercise_price: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F4 · derivative.exercise_price: Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award ("PSU") automatically converted into and was substituted with a restricted stock unit award (each, a "Converted PSU") with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the "Target Shares" (as the term "Target Shares" is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of "Target Shares" as to which, as of immediately prior to the Effective Time, the "Performance-Requirement" has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the "Target Shares" underlying such PSU as to which the "Performance-Requirement" would be satisfied if the "Closing Price" (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over F5 · derivative.exercise_price: (Continued from footnote 4) (B) the number of "Target Shares" as to which, as of immediately prior to the Effective Time, the "Performance-Requirement" has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU. F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F4 · derivative.exercise_date: Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award ("PSU") automatically converted into and was substituted with a restricted stock unit award (each, a "Converted PSU") with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the "Target Shares" (as the term "Target Shares" is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of "Target Shares" as to which, as of immediately prior to the Effective Time, the "Performance-Requirement" has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the "Target Shares" underlying such PSU as to which the "Performance-Requirement" would be satisfied if the "Closing Price" (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over F5 · derivative.exercise_date: (Continued from footnote 4) (B) the number of "Target Shares" as to which, as of immediately prior to the Effective Time, the "Performance-Requirement" has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU. Read SEC document |
| July 14, 2026 Filed Jul 15, 2026 01:45 UTC | XOMA Royalty Corp XOMA · Entity 30207 | OtherCommon Stock | 103,906 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-303720 · ownership.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F2 · shares: At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the "Closing Amount"), plus (ii) an amount of contingent value rights (each, a "CVR") representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the "Merger Consideration"). F3 · shares: At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F2 · price: At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the "Closing Amount"), plus (ii) an amount of contingent value rights (each, a "CVR") representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the "Merger Consideration"). F3 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:30 UTC | XOMA Royalty Corp XOMA · Entity 30207 | Exercise / conversionPerformance Stock Units · Derivative | 11,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-004971 · marketforms-72954.xml · derivative · entry 2 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,924 Underlying: Common Stock · 11,538 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock (the "Common Stock"). The PSUs vest upon the Common Stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer through each vesting date. F1 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock (the "Common Stock"). The PSUs vest upon the Common Stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:30 UTC | XOMA Royalty Corp XOMA · Entity 30207 | Exercise / conversionCommon Stock | 11,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-004971 · marketforms-72954.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2026 Filed Apr 15, 2026 22:13 UTC | XOMA Royalty Corp XOMA · Entity 30207 | Exercise / conversionPerformance Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-004709 · marketforms-72918.xml · derivative · entry 3 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 4,000 shares Expires 2026-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock (the "Common Stock"). The PSUs vest upon the Common Stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer through each vesting date. F1 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock (the "Common Stock"). The PSUs vest upon the Common Stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| April 13, 2026 Filed Apr 15, 2026 22:13 UTC | XOMA Royalty Corp XOMA · Entity 30207 | Tax withholdingCommon Stock | 1,632 | $36.76 | $59,992.32 |
DisclosureSEC source: 0001214659-26-004709 · marketforms-72918.xml · nonDerivative · entry 2 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,368 Read SEC document |
| April 13, 2026 Filed Apr 15, 2026 22:13 UTC | XOMA Royalty Corp XOMA · Entity 30207 | Exercise / conversionCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-004709 · marketforms-72918.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 23:09 UTC | XOMA Royalty Corp XOMA · Entity 30207 | GrantPerformance Stock Units · Derivative | 138,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-003284 · marketforms-72531.xml · derivative · entry 2 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,462 Underlying: Common Stock · 138,462 shares Expires not disclosed F2 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of common stock. The PSUs vest upon the common stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer through each vesting date. F2 · derivative.exercise_date: Each performance stock unit ("PSU") represents a contingent right to receive one share of common stock. The PSUs vest upon the common stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer through each vesting date. F2 · derivative.expiration_date: Each performance stock unit ("PSU") represents a contingent right to receive one share of common stock. The PSUs vest upon the common stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 23:09 UTC | XOMA Royalty Corp XOMA · Entity 30207 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-003284 · marketforms-72531.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 F1 · shares: Represents a grant of restricted stock units payable solely in common stock that will vest as to 25% on each of the first four anniversaries of January 12, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:35 UTC | XOMA Royalty Corp XOMA · Entity 30207 | GrantPerformance Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-000477 · marketforms-71833.xml · derivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2026-05-18 F1 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of XOMA common stock. The PSUs vest upon XOMA's common stock achieving a specified price per share. F1 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of XOMA common stock. The PSUs vest upon XOMA's common stock achieving a specified price per share. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $17.54 | $0.00 |
DisclosureSEC source: 0000950170-24-019458 · ownership.xml · derivative · entry 2 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-02-22 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-019458 · ownership.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,919 F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 1,920 | $8.50 | $16,320.00 |
DisclosureSEC source: 0000950170-23-072754 · ownership.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,919 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 23:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 398 | $8.22 | $3,271.56 |
DisclosureSEC source: 0000950170-23-071985 · ownership.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,839 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 01:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 1,926 | $7.81 | $15,042.06 |
DisclosureSEC source: 0000950170-23-070143 · ownership.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,237 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 01:27 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 2,340 | $9.08 | $21,247.20 |
DisclosureSEC source: 0000950170-23-031858 · ownership.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,163 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 1, 2023. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 20:17 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 399 | $12.94 | $5,163.06 |
DisclosureSEC source: 0000950170-23-029158 · ownership.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,823 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 20:35 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 319 | $13.11 | $4,182.09 |
DisclosureSEC source: 0000950170-23-027985 · ownership.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,222 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:44 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 399 | $8.76 | $3,495.24 |
DisclosureSEC source: 0000899243-23-013358 · doc4.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,541 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| May 12, 2023 Filed May 16, 2023 21:28 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 347 | $8.78 | $3,046.66 |
DisclosureSEC source: 0000950170-23-022548 · ownership.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,940 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 20:34 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 398 | $10.71 | $4,262.58 |
DisclosureSEC source: 0000950170-23-013702 · ownership.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,287 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 22:35 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 318 | $10.22 | $3,249.96 |
DisclosureSEC source: 0000899243-23-011298 · doc4.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,685 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| March 20, 2023 Filed Mar 27, 2023 20:05 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 399 | $11.32 | $4,516.68 |
DisclosureSEC source: 0000899243-23-009718 · doc4.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,003 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 00:01 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 93,500 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0000899243-23-005736 · doc4.xml · derivative · entry 2 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,500 Underlying: Common Stock · 93,500 shares Expires 2033-02-16 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 00:01 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 47,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005736 · doc4.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,402 F1 · shares: The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| December 30, 2022 Filed Jan 6, 2023 18:48 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 201 | $8.97 | $1,802.97 |
DisclosureSEC source: 0000899243-23-001157 · doc4.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,402 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on December 30, 2022. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 22:08 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 1,451 | $10.90 | $15,815.90 |
DisclosureSEC source: 0000899243-22-025080 · doc4.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,201 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2022. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:43 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0000899243-22-006412 · doc4.xml · derivative · entry 2 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-10 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:43 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006412 · doc4.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,750 F1 · shares: The shares underlying the restricted stock unit vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 20:15 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-21-040454 · doc4.xml · derivative · entry 3 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,891 Underlying: Common Stock · 8,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares vested on September 8, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 20:15 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 8,000 | $25.00 | $200,000.00 |
DisclosureSEC source: 0000899243-21-040454 · doc4.xml · nonDerivative · entry 2 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 20:15 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 8,000 | $4.30 | $34,400.00 |
DisclosureSEC source: 0000899243-21-040454 · doc4.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:15 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-21-035417 · doc4.xml · derivative · entry 4 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,891 Underlying: Common Stock · 15,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares vested on September 8, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:15 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 9,513 | $28.85 | $274,450.05 |
DisclosureSEC source: 0000899243-21-035417 · doc4.xml · nonDerivative · entry 3 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $28.40 to $29.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:15 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 5,487 | $27.83 | $152,703.21 |
DisclosureSEC source: 0000899243-21-035417 · doc4.xml · nonDerivative · entry 2 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,763 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $27.40 to $28.38. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:15 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 15,000 | $4.30 | $64,500.00 |
DisclosureSEC source: 0000899243-21-035417 · doc4.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | PurchaseCommon Stock | 2,250 | $21.00 | $47,250.00 |
DisclosureSEC source: 0000899243-21-002047 · doc4.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 22:33 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 146,665 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0000899243-21-001361 · doc4.xml · derivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,665 Underlying: Common Stock · 146,665 shares Expires 2031-01-06 F1 · derivative.exercise_date: The option represents a right to purchase a total of 146,665 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.